2nd Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$570,363
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Generic Drug User Fees Funding for FDA, including, but not limited to any proposal relating to funding for the Office of Generic Drugs FY2010 Presidential Budget Request FY2010 Congressional Budget and Appropriations

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
CHARLES L KINNEY Democratic Chief Floor Counsel
JASON R MONEY —

Contacted: Federal Trade Commission (FTC); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); White House Office; Commerce, Dept of (DOC); Congressional Budget Office (CBO); U.S. Trade Representative (USTR)

Trade (domestic/foreign) TRD

Free Trade Agrements, including but not limited to the Trans-Pacific Partnership FTA Any matters related to international activities with regard to access to generic medicines

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
CHARLES L KINNEY Democratic Chief Floor Counsel
JASON R MONEY —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); White House Office; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Congressional Budget Office (CBO)

Copyright/Patent/Trademark CPT

Patent Reform, including, but not limited to: S.515, S.610, and H.R.1260 Patent Settlements/Reverse Payments/Exclusionary Payments, including, but not limited to: S.369 and H.R.1706 Legislation relating to patent term extensions Any other matter that relates to access to generic drugs

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
CHARLES L KINNEY Democratic Chief Floor Counsel
JASON R MONEY —

Contacted: White House Office; Food & Drug Administration (FDA); Commerce, Dept of (DOC); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Congressional Budget Office (CBO)

Bills named: H.R. 1260 (111th), S. 610 (111th), S. 515 (111th), S. 369 (111th), H.R. 1706 (111th)

Medicare/Medicaid MMM

Medicaid Reimbursement Medicaid Rebates The Deficit Reduction Act of 2006: all provisions relating to prescription drug reimbursement Any other matter that relates to access to generic drugs Average Manufacture Price (AMP)/AMP Publication Medicare Part D Drug Program, expanding rebates to Part D program

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
CHARLES L KINNEY Democratic Chief Floor Counsel
JASON R MONEY —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); U.S. Trade Representative (USTR); SENATE; Commerce, Dept of (DOC); White House Office; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Congressional Budget Office (CBO)

Pharmacy PHA

Generic Biologics, including but not limited to: H.R.1427, H.R.1548, and S.726 Prescription Drug Safety Counterfeit Drugs/Import Safety/Pedigree, such as: H.R.759 Authorized Generics, including, but not limited to: S.501 and H.R.573 Prescription Drug Importation/Re-Importation Any other matters that relate to access to generic drugs

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
CHARLES L KINNEY Democratic Chief Floor Counsel
JASON R MONEY —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); SENATE; HOUSE OF REPRESENTATIVES; White House Office; Congressional Budget Office (CBO); Federal Trade Commission (FTC); U.S. Trade Representative (USTR)

Bills named: H.R. 1427 (111th), H.R. 759 (111th), S. 501 (111th), H.R. 573 (111th), H.R. 1548 (111th), S. 726 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.